These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6752720)

  • 21. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
    Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
    Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High doses of alkylating agents and bone marrow autograft in ovarian cancer with poor prognosis: a retrospective analysis of 40 patients treated in France].
    Maraninchi D; Viens P; Legros M; Oberling F; Philip T; Herve P; Plagne R; Dufour P; Bergerat JP; Guastalla JP
    Bull Cancer; 1990; 77(2):149-57. PubMed ID: 2156587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alkylating agents as leukemogens in multiple myeloma.
    Karchmer RK; Amare M; Larsen WE; Mallouk AG; Caldwell GG
    Cancer; 1974 Apr; 33(4):1103-7. PubMed ID: 4522494
    [No Abstract]   [Full Text] [Related]  

  • 24. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acute leukemia secondary to the treatment of multiple sclerosis with chlorambucil].
    Aymard JP; Witz F; Conroy T; Lederlin P; Humbert JC; Barroche G; Streiff F
    Rev Neurol (Paris); 1985; 141(2):152-4. PubMed ID: 3858929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
    Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE
    Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leukemia incidence following primary breast carcinoma treatment.
    Kaplan HG; Malmgren JA; Atwood M
    Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
    Berk PD; Goldberg JD; Silverstein MN; Weinfeld A; Donovan PB; Ellis JT; Landaw SA; Laszlo J; Najean Y; Pisciotta AV; Wasserman LR
    N Engl J Med; 1981 Feb; 304(8):441-7. PubMed ID: 7005681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An overview of the relationship between alkylating agents and therapy-related acute nonlymphocytic leukemia.
    Uhlenhopp MB
    Cancer Nurs; 1992 Feb; 15(1):9-17. PubMed ID: 1544136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Leukemia in tumor patients receiving chemotherapy].
    Fopp M; Senn HJ
    Dtsch Med Wochenschr; 1985 Sep; 110(38):1439-41. PubMed ID: 3861311
    [No Abstract]   [Full Text] [Related]  

  • 33. Acute myeloid leukemia following non-Hodgkin's lymphoma: danger of prolonged use of chlorambucil as maintenance therapy.
    Dumont J; Thiery JP; Mazabraud A; Natali JC; Trapet P; Vilcoq JR
    Nouv Rev Fr Hematol (1978); 1980; 22(4):391-404. PubMed ID: 6942388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.
    Piver S; Barlow JJ; Chung WS; Lee FT; Vongtama V
    Natl Cancer Inst Monogr; 1975 Oct; 42():177-82. PubMed ID: 825780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer and secondary leukemia.
    Rosner F
    Bull Cancer; 1983; 70(1):55-60. PubMed ID: 6573207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pyoderma gangrenosum, ovarian carcinoma treated with Melphalan and acute myelomonocytic leukaemia: report of one case and literature review (author's transl)].
    Ortonne JP; Thivolet J; Chouvet B; Coiffet J
    Ann Dermatol Venereol; 1979 Mar; 106(3):251-6. PubMed ID: 290349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy related acute non-lymphocytic leukemia: report of 4 cases.
    Atichartakarn V; Punyammalee B; Nitiyanant P
    Southeast Asian J Trop Med Public Health; 1985 Sep; 16(3):421-30. PubMed ID: 4095607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute leukemia and immunosupressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases.
    Grünwald HW; Rosner F
    Arch Intern Med; 1979 Apr; 139(4):461-6. PubMed ID: 373662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience.
    Curtis RE; Hankey BF; Myers MH; Young JL
    J Natl Cancer Inst; 1984 Mar; 72(3):531-44. PubMed ID: 6583439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.